EuroBiotech: More Articles of Note

Newspapers
(NS Newsflash/CC BY 2.0)

> Shares in PharmaMar crashed after the Spanish biotech revealed a phase 3 ovarian cancer trial had missed its primary endpoint. Synthetic tetrahydroisoquinoline alkaloid Zepsyre failed to improve progression-free survival in patients with platinum-resistant ovarian cancer. Statement (PDF)

> Ablynx named Robert Friesen, Ph.D., as its CSO. Friesen joins from ProQR at a time when Ablynx is the subject of takeover interest from Novo Nordisk. Release

> BioCanCell unveiled plans to list its stock in the U.S. The Israeli biotech revealed its IPO intentions in a statement about the pricing of a $25 million (€20 million) financing round. Statement

FREE DAILY NEWSLETTER

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

> Advicenne followed up on its IPO by appointing Linda Law, M.D., to oversee its U.S. clinical trial activities. Release

> Genfit kicked off its pediatric NASH program. Statement

> ImmuPharma raised £10 million ($14 million). Release

Suggested Articles

Novo Nordisk and Dicerna are teaming up on liver-related diseases, including nonalcoholic steatohepatitis (NASH), to the tune of $225 million.

After announcing it was slashing scores of jobs, Alkermes is now willing to put down nearly $1 billion to buy out CNS biotech Rodin Therapeutics.

The top-line readout appears to justify the risk the partners took when they advanced the drug despite missing the primary endpoint in phase 2.